摘要
脓毒症及其严重形式脓毒性休克是重症医学领域中导致患者死亡的主要疾病之一,其发病机制与病程进展复杂,目前尚缺乏有效的治疗方法。多项研究表明,亚甲蓝(MB)可通过抑制一氧化氮(NO)的过量生成、保护线粒体功能、调控炎症小体活化和激活抗氧化通路等机制,改善脓毒性休克患者的血流动力学与短期预后,但对于MB的潜在机制、长期疗效及药物策略的研发仍然不足。本研究旨在探讨MB的药理特性、分子机制并评估其在脓毒性休克中的临床应用前景,以期能够增进对MB治疗潜力的理解,为临床应用提供参考。
Sepsis and its severe form,septic shock,are one of the major diseases leading to patients'death in the field of critical care medicine,and the pathogenesis and course of disease development are complex,and there is still a lack of effective treatments.Several studies have revealed that methylene blue(MB)improves hemodynamics and short-term prognosis in septic shock through multiple mechanisms,including inhibiting excessive nitric oxide production,preserving mitochondrial function,modulating inflammasome activation,and activating antioxidant pathways.However,the potential mechanism,long-term efficacy and drug strategy of MB are still insufficient.This article aims to systematically review the pharmacological properties of MB,elucidate its molecular mechanisms of action,evaluate its clinical application prospects in septic shock,enhance the understanding of the therapeutic potential of MB in order to provide ideas for clinical application.
作者
王嘉凯
谭睿敏
袁静
葛晨
张陈鑫
李磊
韩旭敏
杜全胜
Wang Jiakai;Tan Ruimin;Yuan Jing;Ge Chen;Zhang Chenxin;Li Lei;Han Xumin;Du Quansheng(School of Graduate,Hebei Medical University,Shijiazhuang 050017,China)
出处
《中国急救医学》
2025年第6期528-533,共6页
Chinese Journal of Critical Care Medicine
基金
河北省自然科学基金资助项目(H2020307040)
政府资助临床医学优秀人才培养项目(ZF2020003)
政府资助临床医学优秀人才培养项目(ZF2024008)。
关键词
脓毒性休克
亚甲蓝
一氧化氮
线粒体
炎症小体
Septic shock
Methylene blue
Nitric oxide
Mitochondria
Inflammasomes
